ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Zoledronic Acid ADVAGEN, is now approved in Singapore.

“We are very pleased to announce the approval of Zoledronic Acid ADVAGEN in Singapore. As always, we strive to continue expanding our range of therapeutic products to provide our patients and healthcare providers with alternative options that are safe, effective, and affordable as well.” – Soo, Regulatory Affairs.